MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Bevacizumab improve survival in breast cancer

Back to breast cancer blog Blogs list Cancer blog  


Subscribe To Breast Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Bevacizumab improve survival in breast cancer




Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer as per results of a large clinical trial of Avastin, an anti-angiogenic treatment. The study, reported in the December 27th issue of the New England Journal (NEJM), observed that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer in comparison to chemotherapy alone.

Rush University Medical Center participated in the clinical trial which was sponsored by the National Cancer Institute and conducted by a network of scientists led by the Eastern Cooperative Oncology Group (ECOG).



Bevacizumab improve survival in breast cancer

The study of 722 women with recurrent (metastatic) breast cancer observed that the women who received Avastin in combination with standard chemotherapy had a doubling of delay in worsening of their cancer by approximately five months, on average, in comparison to patients treated with chemotherapy alone. Those on Avastin had progression-free survival of 11.3 months in comparison to 6 months on standard chemotherapy alone.

"This treatment is a one-two punch! You hit the tumor with the chemo and sabotage new blood vessel growth by restricting its oxygen supply with Avastin," said Dr. Melody Cobleigh, co-author of the study and director of the Coleman Foundation Comprehensive Breast Center at Rush. "This is a noteworthy advance in cancer therapy".

Avastin is a therapeutic antibody designed to specifically inhibit vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis and the maintenance of existing blood vessels throughout the lifecycle of a tumor. By inhibiting VEGF, Avastin is designed to interfere with the blood supply to a tumor, which is believed to be critical to a tumors ability to grow and spread in the body.

Avastin not only slowed the growth of the tumor, it also doubled the remission rate (the shrinkage of tumors by 50 percent or more) compared with chemotherapy alone. With chemotherapy, 25% of tumors responded; with the combination of chemotherapy and bevacizumab, 49% did so.

Rush University Medical Center has been involved in the study of Avastin from the very beginning, participating in the Phase I, Phase II and Phase III studies of the drug. The next step is studying the drug in the adjuvant setting to determine if it can help decrease the risk of cancer recurrence.

"The tumor cant grow bigger than the size of a sesame seed without an oxygen supply," said Cobleigh. "And patients can stay on Avastin as long at it works. It is not a chemotherapy drug so it has minimal toxicity. ".

As per the American Cancer Society, an estimated 178,000 women will be diagnosed with breast cancer and approximately 40,000 will die from the disease in the United States in 2007.


Posted by: Janet    Source




Did you know?
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer as per results of a large clinical trial of Avastin, an anti-angiogenic treatment. The study, reported in the December 27th issue of the New England Journal (NEJM), observed that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer in comparison to chemotherapy alone.

Medicineworld.org: Bevacizumab improve survival in breast cancer

BREAST CANCER MAIN| Home| Breast cancer news| Common terms| Breast cancer treatment| Breast cancer treatment by stage| Mammogram and breast cancer screening| Surgical treatment of breast cancer| Chemotherapy of breast cancer| Chemo drugs used in breast cancer| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy of breast cancer| Radiation therapy of breast cancer| Monoclonal therapy| High dose chemotherapy for breast cancer| Recurrent breast cancer| Bisphosphonates and breast cancer| Pregnancy and breast cancer| Risk factors for breast cancer| Risk details| My risk| Comprehensive breast cancer information| Breast cancer statistics| African Americans and breast cancer| Ashkenazi and breast cancer| Asians| Hispanic| Men| Native Americans| Older women and breast cancer| Younger women| Pregnant women and breast cancer| BRCA|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.